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ABSTRACT
A dangerous distortion of priorities seems to be currently
apparent in the dominant approaches to major public
health problems, including cardiovascular disease,
diabetes, obesity, cancer and some infectious diseases.
Relevant examples suggest an apparently inappropriate
tendency to prioritise technocratic, partial solutions
rather than confronting their true behavioural and
structural determinants. Technically oriented preventive
medicine often takes excessive precedence over simpler,
more sensible approaches to modify lifestyles, the
environment and the social structure. Structural factors
(social, cultural, financial, familiar, educational, political
or ideological factors) that act as determinants of
individual behaviours should be effectively addressed to
confront the essential causes of the most prevalent and
important health problems. Some consumer-directed
commercial forces seem to be increasingly driving many
aspects of the current sociocultural environment, and
may eventually compromise the main pursuits of public
health. Population-wide strategies are needed to create a
healthy sociocultural environment and to empower
individuals and make themselves resistant to these
adverse environmental and structural pressures.
Otherwise most public health interventions will most
likely end in failures.
INTRODUCTION
Has costly ‘Preventive Medicine’ taken precedence
over simpler behavioural interventions? It makes
sense to prioritise actions on the small number of
behavioural factors which are the leading determi-
nants of health.1 2 On the contrary, other more
costly technocratic approaches seem to be playing
the dominant role in current public health policies.
Emphasising medical devices over lifestyles can
potentially compromise public health,3 especially
when preventive technologies are applied without
simultaneously addressing the behavioural or struc-
tural underlying determinants of risk.
We have selected some important public health
conditions where this distortion of priorities cur-
rently seems quite conspicuous (table 1).
Table 1 includes major contributors to the global
burden of disease. The headings for each row (left
column) represent sound and effective alternatives.
Some of these interventions are able to confront
several chronic conditions at the same time. In con-
trast, the alternatives placed at the bottom row are
the inefficient and technological solutions that
seem to have been currently prioritised in many
settings.4
LIFESTYLE AND DIET TO PREVENT
CARDIOVASCULAR DISEASE INSTEAD OF THE
STATIN REDUCTIONISM
At least 80% of premature cardiovascular deaths
could be prevented simply through diet, physical
activity and smoking avoidance. However, despite
an increase in the use of antihypertensive and
lipid-lowering drugs, the overall control of classical
risk factors in the last years in Europe has been
poor. Smoking continued unabated, and over-
weight/obesity prevalence increased dramatically.5
Cardiovascular prevention might be futile without
addressing the actual underlying causes of myocar-
dial infarction and stroke.
The 2013 updated American guidelines for car-
diovascular prevention include blood cholesterol
levels in all risk prediction algorithms.6 The stron-
gest recommendation in these guidelines is the
treatment with cholesterol-lowering drugs, mainly
with statins (hydroxymethylglutaryl coenzyme A
reductase inhibitors) for wide sectors of the popu-
lation including subjects with no previous history
of cardiovascular disease (CVD, ie, for primary pre-
vention). However, the massive use of statins for
primary prevention in healthy individuals is contro-
versial. It is well known that statins do effectively
reduce cardiovascular events in selected subgroups
of patients with previous CVD, but the causal
mechanisms leading from blood lipids to major car-
diovascular clinical events need to be more thor-
oughly reappraised: is blood cholesterol really the
major cause of CVD?; is cholesterol reduction the
essential and indispensable step in CVD prevention
for all kind of patients? Have we replaced the
multifactorial origins of CVD by a single risk
factor? It is well known that the best way to market
a drug is the marketing of a disease (or one proxy
of a disease). Are we reductionistically using high
blood cholesterol as a commercially profitable
proxy for CVD? Today, it is becoming more
obvious that it is not LDL-cholesterol that is dir-
ectly implicated in CVD but small, dense, type B
particles generated after a high intake of sugar and
processed carbohydrates.7–9 Overnutrition is
related to blood lipids, and to blood pressure,
resistance to insulin, inflammatory mechanisms,
oxidative stress, coagulation factors and many other
pathways leading to cardiovascular clinical events.
A stronger focus on nutrition instead of the global
oversimplification to massive statin use would have
been the most sensible approach. The continually
widening indication for statin prescription to more
and more millions of healthy people does not seem
to be scientifically justified.10 11 The US guidelines
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as well as the newly updated UK guidelines,12 seem to assume
that the unique solution to the CVD pandemic is the replace-
ment of CVD by a proxy (blood cholesterol) and therefore
justify a blanket-wide use of statins. This oversimplification has
provoked ample criticisms.8 10 13
Do we need to prescribe statins or ‘polypills’ to more than
30% of the general adult population for CVD prevention when
we already know that 80% of CVD events can be prevented
with simple dietary and non-dietary lifestyle measures?14–17 As
the large PREvención con DIeta MEDiterránea (PREDIMED)
primary prevention nutritional trial showed, simple dietary
interventions can prevent many different cardiovascular pro-
blems. Indeed, only a modest increment in the adherence to the
Mediterranean diet supplemented with extra virgin olive oil
(100% fat) or with nuts (>50% fat) obtained a 30% relative
reduction in major cardiovascular events (stroke, myocardial
infarction, cardiovascular death)18 19 and also attained other
cardiovascular benefits in primary prevention.20 21 Improved
adherence to a high-quality dietary pattern has the additional
benefit of enjoying palatable foods and will allow many more
people to live longer without any need of recommending
low-fat diets or using pharmacological solutions which are not
exempt from side effects.15 Yet, even though light to moderate
alcohol intake might reduce cardiovascular mortality,22 being
physically active and eating a healthier diet can be more effect-
ive than drinking a low dose of alcohol, which may have other
undesirable effects.2 23
MEDICATION VERSUS LIFESTYLE IN DIABETES
PREVENTION
Type 2 diabetes (T2D) is likely to become the next major epi-
demic largely as a result of the current obesity pandemic. T2D
will affect more than 10% of the adult population in many
countries during the next two decades, with a projected increase
of 55% by 2035.24 25 T2D is also increasing in the youth.26
However, T2D is largely preventable.27 Up to 91% of T2D
cases could be prevented by relatively modest lifestyle
changes.28 Therefore global growing rates of T2D represent a
profound humiliation for public health. Randomised controlled
trials and longitudinal observational studies have confirmed that
Table 1 Public health problems and their respective technological, behavioural or structural solutions
Preventive measure
Public health issue
All cancers Lung cancer
Cervical
cancer
Cardiovascular
disease Type 2 diabetes Obesity
Not sufficiently prioritised lifestyle interventions
Smoking avoidance ✓ ✓ ✓ ✓ ✓
Alcohol avoidance ✓
Eat less ✓ ✓ ✓ ✓
Weight control ✓ ✓ ✓ ✓
Low energy density diets ✓ ✓
Mediterranean-type diet ✓ ✓ ✓ ✓
↑Fruits and vegetables ✓ ✓ ✓ ✓ ✓
↑Cis-unsaturated fats ✓
↑Cis-unsaturated fish ✓
↓Added sugars ✓ ✓ ✓
↓Trans fats ✓ ✓ ✓
↓Red meats ✓ ✓ ✓ ✓
↓Refined cereals ✓ ✓
Physically active lifestyle ✓ ✓ ✓ ✓ ✓
Pap-screening ✓
Reduction of sexual partners ✓
Delayed sexual debut ✓
Character education* ✓ ✓ ✓ ✓ ✓ ✓
Not sufficiently prioritised structural approaches
Smoke-free spaces ✓ ✓ ✓ ✓ ✓
Raise tobacco prices ✓ ✓ ✓ ✓ ✓
Air pollution control ✓ ✓ ✓
Healthy food affordability ✓ ✓ ✓ ✓ ✓
Trans-fats banning ✓ ✓ ✓
Walking and cycle ways ✓ ✓ ✓ ✓ ✓
Healthy school meals ✓ ✓ ✓
↓Serving size in restaurants ✓ ✓ ✓ ✓
↓Added sugars ✓ ✓ ✓
Sexual attitudes and beliefs ✓
Cultural change (social norms) ✓ ✓ ✓ ✓ ✓
Expensive and dubious technological
‘solutions’
Genetic
testing
Screening (low-dose
CT)
HPV vaccine Statins Metformin,
thiazolidindiones
Antiobesity
drugs
A mark (✓) indicates an appropriate evidence-based preventive intervention.
*Learning process that enables to understand, care about and act, on core values such as respect, justice, civic virtue and citizenship, and responsibility for self and others, which are
the hallmark of safe, healthy and informed communities that serve as the foundation of our society.
CT, computed tomography; HPV, human papillomavirus.
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dietary changes combined with non-dietary lifestyle modifica-
tions can have a long-term effect on T2D prevention.29 30 The
large Diabetes Prevention Program trial (figure 1) in 2002
showed that a lifestyle intervention based on dietary changes
and on physical activity performed better than the metformin-
medicalised option: 58% (lifestyle) versus 31% (metformin)
relative reduction in risk over 3.2 years of follow-up, and 34%
versus 18%, respectively, at 10 years of follow-up.31 32
Furthermore, metformin efficacy was only limited to subjects
with a body mass index >35 kg/m2.31 The outstanding results
of this landmark trial continue today to support the superiority
of lifestyle interventions in comparison with pharmacological
approaches to prevention. This is also true for realistic improve-
ments on different components of the metabolic syndrome and
on the atherogenic dyslipidaemia frequently observed in patients
with diabetes or prediabetes. These nutritional improvements
help to reduce T2D and cardiovascular risk in people with
impaired glucose tolerance.33 34 Moreover, recent evidence sup-
ports that participants in nutrition intervention studies appear
to sustain the dietary changes over time.35 Additionally, pharma-
cological approaches to prevention may have adverse effects.
Metformin has a good record for effectiveness and safety, but
the potential adverse effects of other medications used against
diabetes (eg, thiazolidinediones)36–38 add reasons for caution.
The alarming worldwide prevalence of undiagnosed T2D, with
almost half of all cases still not detected25 is a good reason to
use preventive population-wide dietary and lifestyles strategies.
Thus, lower-cost healthy lifestyles should be the priority for the
global prevention of T2D.27 28 39 The Mediterranean diet, with
a millenary history of no harm, is beneficial for primary cardio-
vascular prevention,40 and to reduce T2D risk.41 Indeed, the
large PREDIMED randomised trial has also recently shown that
changes in the overall dietary pattern with a long-term (up to
7-year follow-up) adoption of the Mediterranean diet can
reduce the risk of T2D among persons at high cardiovascular
risk.30
Another essential strategy for T2D prevention is physical
activity, because physical inactivity is responsible of around 27%
of T2D cases. The promotion of physical activity has been
included in many international clinical guidelines for the
prevention of major chronic diseases.42 43 The new fact sheet of
the WHO recommends that adults should do at least 150 min/
wk of physical activity of moderate intensity.44 However, we are
still far from reaching this recommendation and global levels of
physical activity keep falling.45 46 Public health policies need to
implement effective promotion programmes to make physical
activity accessible and attractive for whole populations. An
active lifestyle can be promoted with correct and specific
instructions to be included in the routines of the general popula-
tion at large. Personal, social and environmental contexts have
to be considered to achieve this purpose.43
The current absence of large randomised trials to assess the
benefits of physical activity using hard clinical end points is
somewhat surprising. Large randomised trials to assess the long-
term effects of physical activity are badly needed.
THE MIRAGE OF ANTIOBESITY DRUGS
Worldwide, around 35% of the adult population are overweight
and 12% are obese.47 48 The prevalence of overweight and
obese children and adolescents is also rapidly increasing,49–51
with an expected 9.1% worldwide prevalence in 2020.52–54
One temptation is to seek ‘technological’ or pharmaceutical
solutions which allow to eat calorie-dense foods ad libitum and
still not become obese. But the story of what has happened with
several seemingly ‘magic’ antiobesity drugs is instructive: some
were rejected by the food and drug administration (FDA),
others were withdrawn from the market or are still awaiting
decisions because of safety concerns.55–57 Although it is easier
for doctors and patients to turn to a pill than to address behav-
iour, we likely do not need more antiobesity drugs trials but a
change of paradigm.58 59 The problem is that our culture,
which advertises how to eat more, resists the simple message
‘eat less’.3 An obesogenic environment is a strong determinant
of the current obesity epidemic. However, not all subjects
exposed to this environment become obese. Susceptible indivi-
duals become obese, whereas resistant subjects remain lean. A
strong hedonistic attraction to palatable foods and to overeating
has proven to be a decisive factor to explain weight gain in an
obesogenic environment.60 Given the actual prevalence of
obesity and its worrisome health consequences, the population
would benefit more from being turned towards attractive and
high-quality lighter meals, with an adequate proportion of the
evidence-based recommended foods.
CANCER: COMPUTED TOMOGRAPHY SCREENING
The development of the ‘omics’ sciences (genomics, transcrip-
tomics, proteomics, metabolomics) has contributed to oversha-
dowing the fact that it is not genetic predisposition but social,
environmental and behavioural factors which cause most
cancers.2 61–63 The good news is that these environmental and
behavioural factors are modifiable.64
Twelve forms of cancer are the major global contributors to
deaths by neoplasia (figure 2). The cancer which causes most
deaths—lung cancer—is the one that could be most easily and
cost-effectively prevented, just by altering behavioural (active
smoking) and environmental (passive smoking) factors.65–67
Expensive screening of lung cancer with low-dose CT has
been recently endorsed by the United States Preventive Services
Task Force (USPSTF) in high-risk subjects because of their
tobacco smoking history.68 However, this approach, which has
important harms associated with false positive results, overdiag-
noses and radiation, cannot prevent most lung cancer-related
deaths, as it results in only a 16% reduction in lung cancer mor-
tality.68 In comparison, a near 40% reduction in lung cancer
Figure 1 Cumulative incidence of type 2 diabetes in the Diabetes
Prevention Program trial (n=3234). p<0.001 for all comparisons.
Among participants with BMI <35 kg/m2 (n=2040), no significant
differences were found between metformin and placebo. ‘From
(Knowler et al31 Copyright (2002) Massachusetts Medical Society.
Reprinted with permission from Massachusetts Medical Society).’
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deaths was already attributed to decreases in smoking in the
past century69 and a 90% risk reduction for overall
smoking-associated mortality has been recently estimated.70
The lure of a high tech screening device can overshadow the
fact that billions of cigarettes are still smoked worldwide every
day and that the number of smokers is increasing in many coun-
tries.69 71 Nineteen types of cancer are attributable to tobacco
smoking.63 Is it not worthy to tackle, as the first priority, this
common cause of a largely lifestyle-associated disease projected
to keep increasing?69 Tobacco retail prices remain too low in
some countries and although tobacco has become less affordable
in some countries it is now more affordable in many others
(figure 3). Sadly, the global burden of disease attributable to
tobacco smoking (including secondhand smoke) has changed
little.2
Screening costs were not considered in the USPSTF and other
guidelines67 68 and screening is not an alternative to smoking
cessation but an additional intervention. Therefore, governmen-
tal actions must focus first on tobacco-avoiding policies.72–79
The priority in lung cancer prevention is not screening
Figure 2 Major cancers in the world.
Projections of mortality from the most
frequent cancers for 2015. Source:
WHO. Mortality and global health
estimates. Cause-specific mortality.
Projections of number of deaths for
2015–2030. http://apps.who.int/gho/
data/node.main.PROJNUMWORLD?
lang=en (accessed 17 Mar 2014).
Figure 3 Cigarette affordability growth rates, 1990–2006. The countries are sorted by income status and then by growth in affordability. Positive
growth in relative income price means that cigarettes have become less affordable. Reproduced with permission from Tob Control 2009;18:167–75.
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(secondary prevention) but complete avoidance of smoking
(primary prevention) and even primordial prevention to com-
pletely eradicate the existence of smoking in our societies and
prevent the initiation of smoking for all members of future
generations.61 69 80
The above-mentioned non-communicable diseases (NCDs)
are largely preventable by addressing common lifestyle determi-
nants (unhealthy diet, physical inactivity and tobacco use).81 82
A recent modelling study has analysed the potential impacts in
NCD mortality of reducing six selected preventable risk factors
(tobacco, alcohol, salt intake, obesity, raised blood pressure and
raised blood glucose). It has concluded that achieving the reduc-
tion of these six risk factors will decrease the probability of pre-
mature deaths from 2010 to 2025 by 33% from CVDs, 12%
from lung cancer and 5% from diabetes.83 Therefore, socio-
logical and cultural issues need to be fully addressed and require
educational and structural responses.84–89 From an equity per-
spective, environments should make the healthier choice the
easiest choice so that prevention becomes accessible, available
and affordable to all sectors of the population.57 58 90–94 On the
other hand, energy-dense fast foods, sugar sweetened beverages,
smoking and sedentary lifestyles should be made the harder
options. These are not sweet truths for some food or beverage
corporations or for the technocratic business,39 95 but they are
indeed the priorities for public health.
HPV VACCINE: THE GLAMOUR OF TECHNOPREVENTION
Also, some approaches to the prevention of communicable
diseases have apparently forgotten the need to give appropriate
priority to lifestyle interventions and heavily relied on techno-
cratic solutions. Universal policies to vaccinate girls against
human papillomavirus (HPV) were adopted very rapidly
during 2006–2009. The technical merits of this vaccine should
be acknowledged and appreciated. However, many issues on this
publicly funded mass vaccination remain unsolved: its coverage
and affordability for the most vulnerable and affected countries,
its long-term effectiveness and the uncertain—though potential
—replacement of the vaccine-targeted strains with other high-
risk types.96–98 Strong conflicts of interest are another reason for
concern as available trials were sponsored by the manufacturers.
Affordability and an adequate coverage with complete vaccine
regimens are two essential components for HPV vaccination
programmes success. The vaccination programmes have mostly
been implemented and publicly funded in higher-income coun-
tries although most of them have very low rates of HPV-related
diseases.99 The rapid introduction of this publicly funded
vaccine in Spain does not match the epidemiological needs of
the country because there is no epidemic of cervical cancer in
Spain whatsoever. On the contrary, mortality and incidence of
cervical cancer are very low and show a decreasing trend in
Spanish women (figure 4).
In developed countries the coverage and effectiveness are
lower for girls at higher risk.100 In addition, very few develop-
ing countries have introduced HPV vaccine into their national
programmes although the burden of HPV-related diseases is
highest there. At the current cost, mass vaccination is unafford-
able in low-income and middle-income countries. In Africa,
although several countries are implementing HPV vaccine
demonstration projects, only Rwanda initiated a countrywide
vaccination, after receiving a donation of several million vaccine
doses from the manufacturer.101 102 The Global Alliance for
Vaccines and Immunisation has offered some of the world’s
poorest countries the quadrivalent vaccine at $4.50/dose. But
overall, vaccination programmes will still be prohibitively
expensive and their widespread implementation will not prob-
ably be sustainable.
Moreover, vaccine efficiency heavily depends on an adequate
coverage with the complete regimen103 and we do not yet know
the long-term efficacy even when a high coverage is reached.
Today, HPV vaccine coverage is still quite low in many coun-
tries, including economically developed countries such as the
USA, where coverage for adolescent girls with all three doses
was 33.4% in 2012.
Is the vaccination supplanting the need to combat the major
risk factors? Why has an expensive and only partially preventive
measure been rapidly introduced while other well-known and
sufficiently proven measures been downgraded?
The rates of cervical cancer in a country are highly dependent
on the availability of and women compliance with screening pro-
grammes. HPV infection strongly depends on partners’ number
and other sexual risk behaviours. Long-term primary prevention
strategies are needed, which include structural interventions and
sexual education with correct and complete information to
increasing awareness about the basic facts of HPV infection. These
simple, affordable and sustainable measures are absolutely essential
for cancer prevention, especially in developing countries.
RISK COMPENSATION
If preventive strategies focus preferentially on glamorous
technological options, apart from the problems herein
described, another important unexpected consequence is risk
compensation. People may consider themselves healthy enough
when they eat foods labelled as low-energy/low-fat, take the pre-
scribed pills and vaccines or attend the recommended screening
programmes no matter if they keep sedentary, adhere to low-
quality food patterns, smoke or have many other dietary and
non-dietary risk behaviours. For example, the new USPSTF
guidelines for lung cancer screening notice that people may
keep on smoking thinking that screening programmes can
reduce their smoking-related risks.68 Believing in a new prevent-
ive technology may lead to a dangerous sense of immunity. The
available evidence is not fully consistent, but risk compensation
has also been associated with HPV vaccine acceptability and this
affects vaccine coverage and consequently, effectiveness and effi-
ciency.96 97 99 103 Therefore, it is important that preventive mes-
sages address the specific target population groups in which
these biomedical strategies are to be recommended so that no
erroneous beliefs turn up. Always, apart from the high-risk sub-
jects, the general population needs to be correctly informed
because population-wide strategies to promote healthy lifestyles
are frequently the most cost-effective option.57
COMMON BUILDING BLOCKS: EMPOWERMENT AND
STRUCTURAL CHANGES
Screening, diagnosis and treatment represent real breakthroughs
and have accounted for tremendous advances in health status.
In fact, the technological preventive interventions mentioned in
this paper can surely have some role and should be applied
when they are appropriately justified. However, the unprece-
dented and continuous increase in the use of pharmacological/
technological approaches, confirms that these approaches might
not be adequate to manage the complex pathogenesis and con-
sequences of chronic diseases. In addition, the partially success-
ful pharmacological/technological approaches are responsible
for inevitable and unsustainable increases in health expendi-
tures; hence, alternative lifestyle and dietary strategies should be
given a sufficiently high priority. A body of sound epidemio-
logical evidence exists to support the effectiveness of diet and
Carlos S, et al. J Epidemiol Community Health 2014;68:897–904. doi:10.1136/jech-2014-203884 901
Review
lifestyles in the prevention of NCD. The technologically driven
mentality might lead us further away from, rather than closer
to, simpler, sensible approaches to the main behaviour-related
public health problems. Only the societal and cultural
approaches confront the root causes.
A common denominator for all the examples reviewed is that
our culture fosters behaviours mainly driven by pleasure-seeking
which are known to be associated with a clustering of unhealthy
lifestyles. Some global commercial powers have fostered a
pleasure-seeking cultural environment which rich and the poor
sectors of society. In this context, cultural deprivation seems
more important than monetary poverty and needs to be coun-
terbalanced by the cultural empowerment of individuals. This
empowerment of individuals is needed to make them resistant
to an environmental pressure favouring unhealthy behaviours.88
However, the success of individually focused interventions
might be substantially improved when wider structural factors
(social, cultural, familiar, educational, political or ideological
factors) that act as determinants of individual behaviours are
also addressed.69 As Geoffrey Rose already stated, population-
based approaches addressing these structural determinants of
health should be prioritised.104 We need to incorporate inter-
ventions that modify the environment through all public and
private policies, in line with the idea of ‘Health in All Policies’.
They will facilitate healthy choices that depend strongly on cir-
cumstances beyond individual control. Today people cannot
make choices about behaviours in the circumstances of their
own choosing. On the contrary, the promotion, price, availabil-
ity and marketing of products affect their perceived costs and
benefits, and consequently their choices. Decisions about life-
styles depend now on choices/interests of governments, produ-
cers and multinational companies and consequently, on the
incentives of financial institutions. A few powerful institutions
and decision-makers who set the agenda and decide what is
fashionable and what is not, are making unhealthy choices the
easiest choices, shaping the preferences of the population at
large and encouraging them to make unhealthy choices.
Consequently, as a result of the conflict with the dominant eco-
nomical interests, wealth is being placed before health and an
overemphasis on expensive technologies has led to underfunded
prevention strategies. Public health intervention policies are
often failing to overcome these powerful forces.105
We acknowledge that the needed cultural change is not easy.
Cultivating an environment where healthier options are encour-
aged requires entering in decision arenas and counteracting
commercially driven forces investing millions in advertising and
opinion-making. Therefore, it does not always conform with
the ‘politically correct’ positions and it is far from cheap and
simple to achieve. However, if sociocultural and normative
changes are attained, they will lead to dramatic reversals of epi-
demics. We do not need to shape individuals’ minds to fit our
increasingly unhealthy societies but we need to redesign the
environment to fit our populations’ health.
The implementation of all the strategies proposed here should
be considered a priority for public health.
What is already known on this subject?
▸ Reducing some of the main preventable risk factors described
here (tobacco, alcohol, salt intake, high blood pressure and
blood glucose and diabetes) will lead to higher reductions in
probability of death compared with current trends with no
additional action (22% in men and 19% in women) and even
more in case of early action (24% and 21%).83
What this study adds?
▸ The new guidelines for cardiovascular prevention can be
misinterpreted and lead to an excessive use of statins; statin
use should be decided depending on individual circumstances.
▸ The growing trends in type 2 diabetes (T2D) prevalence
represent a humiliation for public health because T2D is
easily prevented with diet and lifestyle.
▸ The key message for obesity prevention is “to eat less”.
▸ Screening for lung cancer is probably inefficient and not
affordable and may distort the true priority: smoking avoidance.
▸ Technoprevention with HPV vaccination can backfire without
addressing the true underlying behavioural determinants of risk.
Figure 4 Trends of estimated cervical
cancer mortality rates in Spanish
regions (1975–2004). Vaccination in
Spain began in 2007. Reproduced with
permission from Elsevier. Original
article: Rodríguez-Rieiro et al106.
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